ICE Bioscience provides end-to-end biomarker discovery and detection services designed to accelerate drug development and enhance therapeutic decision-making. From sample collection and processing to biomarker validation and quantification, our advanced platforms and scientific expertise ensure the accurate identification of critical biomarkers. Whether you're in early-stage discovery or clinical development, our services support robust, data-driven insights for drug efficacy, safety assessment, and patient stratification.
ICESTP™ SafetyOne44 and ICESTP™ SafetyMax90, developed by ICE Bioscience, are cutting-edge functional safety panels designed to revolutionize pharmaceutical research. Our panels provide a competitive advantage, enabling early identification of potential off-target adverse drug reactions (ADRs) and informed decision-making, ultimately leading to the development of safer and more effective drugs.
Cardiac safety assessment is a critical component of the drug development process, aimed at identifying potential adverse effects of pharmaceutical compounds on the heart. The significance of these evaluations lies in their capacity to prevent drug-induced cardiac arrhythmias, which can lead to serious health outcomes, including sudden cardiac death. By systematically identifying and mitigating these risks early in drug development, cardiac safety assessments protect patient health and contribute to the development of safer therapeutic options.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
